Literature DB >> 19712170

Helicobacters and extragastric diseases.

Rinaldo Pellicano1, Francesco Franceschi, Giorgio Saracco, Sharmila Fagoonee, Davide Roccarina, Antonio Gasbarrini.   

Abstract

For two decades, Helicobacter pylori has been considered as the culprit in many extragastric manifestations. However, for several of these supposed associations the hypothesis of an etiological role has not yet been fully investigated. This may be due to a series of factors linked to the epidemiological features of the studies and to the diseases investigated. This review attempts to highlight the main reported associations of H. pylori with extragastric manifestations during the last year. The most convincing data arise in the field of idiopathic thrombocytopenic purpura (ITP) and sideropenic anemia. Long-term follow-up studies have shown that 50% of subjects with ITP maintain a hematological response after H. pylori eradication. There is also growing evidence of the role of H. pylori in other diseases, including ischemic heart disease even though results are not conclusive.

Entities:  

Mesh:

Year:  2009        PMID: 19712170     DOI: 10.1111/j.1523-5378.2009.00699.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  22 in total

Review 1.  Flagellin glycosylation with pseudaminic acid in Campylobacter and Helicobacter: prospects for development of novel therapeutics.

Authors:  Abu Iftiaf Md Salah Ud-Din; Anna Roujeinikova
Journal:  Cell Mol Life Sci       Date:  2017-10-27       Impact factor: 9.261

Review 2.  Consequences of Helicobacter pylori infection in children.

Authors:  Lucia Pacifico; Caterina Anania; John F Osborn; Flavia Ferraro; Claudio Chiesa
Journal:  World J Gastroenterol       Date:  2010-11-07       Impact factor: 5.742

3.  Prevalence of virulent Helicobacter pylori strains in patients affected by idiopathic dysrhythmias.

Authors:  Francesco Franceschi; Donatella Brisinda; Francesco Buccelletti; Maria Pia Ruggieri; Antonio Gasbarrini; Annarita Sorbo; Davide Marsiliani; Angela Venuti; Peter Fenici; Giovanni Gasbarrini; Nicolò Gentiloni Silveri; Riccardo Fenici
Journal:  Intern Emerg Med       Date:  2011-05-12       Impact factor: 3.397

Review 4.  Hematologic manifestations of Helicobacter pylori infection.

Authors:  Germán Campuzano-Maya
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

Review 5.  Approach to Helicobacter pylori infection in geriatric population.

Authors:  Sevdenur Cizginer; Zehra Ordulu; Abdurrahman Kadayifci
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-08-06

Review 6.  An association between Helicobacter pylori and upper respiratory tract disease: fact or fiction?

Authors:  Shin Kariya; Mitsuhiro Okano; Kazunori Nishizaki
Journal:  World J Gastroenterol       Date:  2014-02-14       Impact factor: 5.742

7.  Helicobacter pylori seropositivity in diabetic patients is associated with microalbuminuria.

Authors:  Goh Eun Chung; Nam Ju Heo; Min Jung Park; Su Jin Chung; Hae Yeon Kang; Seung Joo Kang
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

8.  Antibodies anti-CagA cross-react with trophoblast cells: a risk factor for pre-eclampsia?

Authors:  Francesco Franceschi; Nicoletta Di Simone; Silvia D'Ippolito; Roberta Castellani; Fiorella Di Nicuolo; Giovanni Gasbarrini; Yoshio Yamaoka; Tullia Todros; Giovanni Scambia; Antonio Gasbarrini
Journal:  Helicobacter       Date:  2012-06-29       Impact factor: 5.753

9.  Helicobacter pylori immunization and atopic dermatitis in South Italian children.

Authors:  Marcella Pedullà; Vincenzo Fierro; Ester Del Tufo; Rossella Alfano; Maria Triassi; Laura Perrone
Journal:  United European Gastroenterol J       Date:  2014-08       Impact factor: 4.623

10.  Anti-Helicobacter pylori activity of some newly synthesized derivatives of xanthone.

Authors:  Karolina Klesiewicz; Elżbieta Karczewska; Alicja Budak; Henryk Marona; Natalia Szkaradek
Journal:  J Antibiot (Tokyo)       Date:  2016-03-30       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.